Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Eli Lilly said it expects to release data ... weight after that same time period. Higher doses of tirzepatide helped patients with obesity lose up to 22.5% of their body weight on average in ...